Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Updates on the treatment of MDS

Sangmin Lee • 20 Oct 2021
LLM 2021
Myelodysplastic Syndromes Antibodies Cedazuridine Cemiplimab Decitabine Magrolimab Venetoclax

Sangmin Lee, MD, Weill Cornell Medicine, New York, NY, outlines new treatments for high-risk myelodysplastic syndromes (MDS). The current standard of care includes hypomethylating agents and recent advancements include oral decitabine and cedazuridine, which represent a convenient option for patients. Venetoclax, which has been approved in acute myeloid leukemia (AML) and hypomethylating agents, as well as cemiplimab or magrolimab with azacytidine, are additional promising treatment regimens in patients with high-risk MDS. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

More from Sangmin Lee

1:07
Challenges in treating AML
Sangmin Lee • 20 Oct 2021
1:13
Rare blood diseases at LLM 2021
Sangmin Lee • 20 Oct 2021
2:10
Updated overall survival data on eltanexor for HMA-refractory MDS
Sangmin Lee • 4 Jun 2021
1:17
Phase II study of tosedostat in MDS
Sangmin Lee • 4 Jun 2021

Related Videos

1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals